BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 19596111)

  • 21. Consequences of increased antibacterial consumption and change in pattern of antibacterial use in Danish hospitals.
    Jensen US; Skjøt-Rasmussen L; Olsen SS; Frimodt-Møller N; Hammerum AM;
    J Antimicrob Chemother; 2009 Apr; 63(4):812-5. PubMed ID: 19240071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antimicrobial resistance after antibiotic use in animals--impact on human health].
    Sundsfjord A; Sunde M
    Tidsskr Nor Laegeforen; 2008 Nov; 128(21):2457-61. PubMed ID: 19096469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antimicrobial usage in paediatric intensive care units in China.
    Ding H; Yang Y; Chen Y; Wang Y; Fan S; Shen X
    Acta Paediatr; 2008 Jan; 97(1):100-4. PubMed ID: 18076718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibiotic consumption in southern and eastern Mediterranean hospitals: results from the ARMed project.
    Borg MA; Zarb P; Ferech M; Goossens H;
    J Antimicrob Chemother; 2008 Oct; 62(4):830-6. PubMed ID: 18593724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bacterial resistance in the new millennium. Its impact on antibiotic selection for respiratory tract infections.
    Appelbaum PC
    Postgrad Med; 2000 Dec; 108(7 Suppl Contemporaty):5-16. PubMed ID: 19667544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New developments in carbapenems.
    Kattan JN; Villegas MV; Quinn JP
    Clin Microbiol Infect; 2008 Dec; 14(12):1102-11. PubMed ID: 19076841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of limiting antimicrobial therapy duration on antimicrobial resistance in the critical care setting.
    Marra AR; de Almeida SM; Correa L; Silva M; Martino MD; Silva CV; Cal RG; Edmond MB; dos Santos OF
    Am J Infect Control; 2009 Apr; 37(3):204-9. PubMed ID: 18986735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistance of nasopharyngeal pathogens and antimicrobial prescription rates for children in an area under controlled antimicrobial use.
    Otsuka T; Ono T; Okazaki M
    Pediatr Infect Dis J; 2009 Feb; 28(2):128-30. PubMed ID: 19106776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of poverty in antimicrobial resistance.
    Planta MB
    J Am Board Fam Med; 2007; 20(6):533-9. PubMed ID: 17954860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Off-label use of antibiotics in hospitalized patients: focus on tigecycline.
    Curcio D
    J Antimicrob Chemother; 2009 Dec; 64(6):1344-6. PubMed ID: 19759045
    [No Abstract]   [Full Text] [Related]  

  • 31. A review of tigecycline--the first glycylcycline.
    Peterson LR
    Int J Antimicrob Agents; 2008 Dec; 32 Suppl 4():S215-22. PubMed ID: 19134522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of anaerobic infection.
    Brook I
    Expert Rev Anti Infect Ther; 2007 Dec; 5(6):991-1006. PubMed ID: 18039083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Performance of the TREAT decision support system in an environment with a low prevalence of resistant pathogens.
    Kofoed K; Zalounina A; Andersen O; Lisby G; Paul M; Leibovici L; Andreassen S
    J Antimicrob Chemother; 2009 Feb; 63(2):400-4. PubMed ID: 19091808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preventing bacterial resistance in surgical patients.
    Evans HL; Sawyer RG
    Surg Clin North Am; 2009 Apr; 89(2):501-19, x. PubMed ID: 19281897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tigecycline.
    Prescrire Int; 2007 Dec; 16(92):245. PubMed ID: 18092414
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibiotic consumption and link to resistance.
    Goossens H
    Clin Microbiol Infect; 2009 Apr; 15 Suppl 3():12-5. PubMed ID: 19366364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model.
    Zhanel GG; Baudry PJ; Tailor F; Cox L; Hoban DJ; Karlowsky JA
    J Antimicrob Chemother; 2009 Oct; 64(4):824-8. PubMed ID: 19643776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Has the era of untreatable infections arrived?
    Livermore DM
    J Antimicrob Chemother; 2009 Sep; 64 Suppl 1():i29-36. PubMed ID: 19675016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antimicrobial stewardship.
    Allerberger F; Mittermayer H
    Clin Microbiol Infect; 2008 Mar; 14(3):197-9. PubMed ID: 18190577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimizing drug exposure to minimize selection of antibiotic resistance.
    Olofsson SK; Cars O
    Clin Infect Dis; 2007 Sep; 45 Suppl 2():S129-36. PubMed ID: 17683017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.